Printer Friendly

Herantis granted approval by Finnish Medicines Agency Fimea for its Parkinson's disease clinical trial.

M2 EQUITYBITES-June 12, 2017-Herantis granted approval by Finnish Medicines Agency Fimea for its Parkinson's disease clinical trial

(C)2017 M2 COMMUNICATIONS http://www.m2.com

Finnish Medicines Agency Fimea has authorised Herantis Pharma plc's (HEL: HRTIS) first-in-human clinical study of its investigational product CDNF for the treatment of Parkinson's disease, the Finnish drug development company reported on Monday.

The news follows Herantis' announcement earlier this year that it had secured approval for the same clinical study in Sweden.

The first study site to begin patient recruitment will be the Karolinska University Hospital in Stockholm, Sweden, although the company has decided to postpone the launch of patient recruitment until the third quarter of 2017.

Herantis deemed this necessary due to the local holidays taking place that could otherwise disrupt the trials. Moreover, by waiting the company will be able to secure optimal resources as well as the safety of the patients.

The study is set to include 18 patients with Parkinson's disease. Of these, a subset will be given a placebo infusion instead of CDNF, in a blinded manner. Herantis hopes that this setup will deliver a strong initial assessment of the effects of CDNF.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Geographic Code:4EUSW
Date:Jun 12, 2017
Words:205
Previous Article:DNA reports on repurchase of own shares.
Next Article:Alibaba Cloud to open two new data centres in India and Indonesia.
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters